KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Bristol Myers Squibb (BMY) Accumulated Depreciation & Amortization (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Accumulated Depreciation & Amortization for 17 consecutive years, with $4.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 58.22% to $4.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0 billion, a 58.22% decrease, with the full-year FY2025 number at $4.0 billion, down 58.22% from a year prior.
  • Accumulated Depreciation & Amortization was $4.0 billion for Q4 2025 at Bristol Myers Squibb, up from $3.0 billion in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $10.7 billion in Q4 2021 to a low of $1.0 billion in Q1 2025.
  • A 5-year average of $5.6 billion and a median of $5.1 billion in 2022 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: rose 7.71% in 2021, then tumbled 60.7% in 2025.
  • Bristol Myers Squibb's Accumulated Depreciation & Amortization stood at $10.7 billion in 2021, then fell by 3.84% to $10.3 billion in 2022, then fell by 5.02% to $9.8 billion in 2023, then dropped by 1.64% to $9.6 billion in 2024, then crashed by 58.22% to $4.0 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Accumulated Depreciation & Amortization are $4.0 billion (Q4 2025), $3.0 billion (Q3 2025), and $2.0 billion (Q2 2025).